The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Sorafenib in advanced clear-cell renal-cell carcinoma.
We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma. ⋯ As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects. (ClinicalTrials.gov number, NCT00073307 [ClinicalTrials.gov].).
-
Randomized Controlled Trial Multicenter Study Comparative Study
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted. ⋯ Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa (ClinicalTrials.gov numbers, NCT00098657 and NCT00083889 [ClinicalTrials.gov]).
-
Case Reports Retracted Publication
Images in clinical medicine. Complication of central venous catheterization.